These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 18442506)

  • 21. What is the potential role of cannabinoid-1 receptor blockade in glucose and lipid management?
    Jensen MD
    Am J Med; 2007 Sep; 120(9 Suppl 1):S25-31; discussion S31-2. PubMed ID: 17720358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The endocannabinoid system and the control of glucose homeostasis.
    Nogueiras R; Rohner-Jeanrenaud F; Woods SC; Tschöp MH
    J Neuroendocrinol; 2008 May; 20 Suppl 1():147-51. PubMed ID: 18426514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endocannabinoids, blood pressure and the human heart.
    Sarzani R
    J Neuroendocrinol; 2008 May; 20 Suppl 1():58-62. PubMed ID: 18426501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.
    Hollander P
    Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The endocannabinoid system as a target for obesity treatment.
    Aronne LJ; Pagotto U; Foster GD; Davis SN
    Clin Cornerstone; 2008; 9(1):52-64; discussion 65-6. PubMed ID: 19046740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome.
    Kyrou I; Valsamakis G; Tsigos C
    Ann N Y Acad Sci; 2006 Nov; 1083():270-305. PubMed ID: 17148745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rimonabant: new data and emerging experience.
    Wright SM; Dikkers C; Aronne LJ
    Curr Atheroscler Rep; 2008 Feb; 10(1):71-8. PubMed ID: 18366988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity.
    Patel PN; Pathak R
    Am J Health Syst Pharm; 2007 Mar; 64(5):481-9. PubMed ID: 17322160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rimonabant.
    Henness S; Robinson DM; Lyseng-Williamson KA
    Drugs; 2006; 66(16):2109-19; discussion 2120-1. PubMed ID: 17112304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The endocannabinoid system and cardiovascular risk: pathophysiologic role and developing therapeutic interventions.
    Sander GE; Giles TD
    Am J Geriatr Cardiol; 2006; 15(4):255-9. PubMed ID: 16849895
    [No Abstract]   [Full Text] [Related]  

  • 31. [Endocannabinoids--the new option in the treatment of metabolic syndrome and in smoking cessation].
    Kvasnicka T
    Cas Lek Cesk; 2005; 144(2):81-4; discussion 85. PubMed ID: 15807291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The endocannabinoid system: a promising target for the management of type 2 diabetes.
    Scheen AJ
    Curr Protein Pept Sci; 2009 Feb; 10(1):56-74. PubMed ID: 19275673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
    Van Gaal LF; Scheen AJ; Rissanen AM; Rössner S; Hanotin C; Ziegler O;
    Eur Heart J; 2008 Jul; 29(14):1761-71. PubMed ID: 18417461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The unfolding cannabinoid story on energy homeostasis: central or peripheral site of action?
    Horvath TL
    Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S30-2. PubMed ID: 16570102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients.
    Dibble CT; Gelfand EV; Cannon CP
    Curr Atheroscler Rep; 2007 Nov; 9(5):359-66. PubMed ID: 18001618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation.
    Tucci SA; Halford JC; Harrold JA; Kirkham TC
    Curr Med Chem; 2006; 13(22):2669-80. PubMed ID: 17017918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of blockage of the endocannabinoid system by CB(1) antagonism on cardiovascular risk.
    Mach F; Montecucco F; Steffens S
    Pharmacol Rep; 2009; 61(1):13-21. PubMed ID: 19307689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: efficacy.
    Aronne LJ; Isoldi KK
    Am J Cardiol; 2007 Dec; 100(12A):18P-26P. PubMed ID: 18154742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The endocannabinoid system: a new pharmacological target for obesity treatment?
    Hu J; Zhu C; Huang M
    Neurosci Bull; 2009 Jun; 25(3):153-60. PubMed ID: 19448689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data.
    Bronander KA; Bloch MJ
    Vasc Health Risk Manag; 2007; 3(2):181-90. PubMed ID: 17580728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.